Drug Profile
CA 88
Alternative Names: CA-88Latest Information Update: 28 Jan 2015
Price :
$50
*
At a glance
- Originator Medigreen Biotechnology Corporation
- Class Chemoprotectants; Radioprotectives
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chemotherapy-induced damage; Radiation injuries
Most Recent Events
- 27 Jan 2015 Discontinued - Phase-I for Chemotherapy induced damage (Prevention) in Taiwan (PO)
- 20 Jul 2007 Phase-I clinical trials in Chemotherapy induced damage (Prevention)/Chemoprotection in Taiwan (PO)
- 20 Jul 2007 Phase-I clinical trials in Radiation injuries (Prevention)/Radioprotection in Taiwan (PO)